Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
T.PYR: Contract Toward Titanium Powder Supply & Distribution Agreement with Asian Materials Co. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Bicara Therapeutics Inc BCAX

Healthcare Biotechnology
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company... see more

Recent & Breaking News (NDAQ:BCAX)

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 7 days ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire 11 days ago

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

GlobeNewswire March 23, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2026

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 26, 2026

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire February 24, 2026

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire February 24, 2026

Bicara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 23, 2026

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

GlobeNewswire February 19, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 5, 2026

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

GlobeNewswire January 12, 2026

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

GlobeNewswire December 15, 2025

Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

GlobeNewswire December 6, 2025

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

GlobeNewswire December 1, 2025

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 10, 2025

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC 

GlobeNewswire October 13, 2025

Bicara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 12, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

GlobeNewswire June 11, 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire June 3, 2025

Podcasts